Company (Symbol) | Offer Date | Number Shares/Units (M) |
Price Per ($M)* |
Gross ($M) |
Net Out (M) | Shares |
Fully Diluted Share/Unit ($) | Post-Offering Market Cap ($M) | Lead UnderWriter | Other UnderWriters |
CV Therapeutics Inc. (CVTX) | 1/22 | 2.58 |
$8.25 |
$21.2 | $19.7 |
11.0 |
13.9 | 91 |
JPM |
UBS, IA |
Pharmacyclics Inc. (PCYC) |
1/30 |
2.01S |
$21.75 |
$43.8 | $40.9 | 12.2 | 13.6 |
264 |
HQ | CC, PGE |
GelTex Pharmaceuticals Inc. (GELX) | 3/19 | 3.0S |
$27.00 | $81.0 |
$62.3 | 16.1 | 17.6 |
436 |
CC | CIBCO,HQ |
NeuroSearch A/S (1) | 3/31 | 0.44S |
$81.03 |
$35.3 | $33.3 | 6.3 | ND | 510 |
SBCW |
UBS,CB, AS |
Triangle Pharmaceuticals Inc. (VIRS) | 4/9 | 4.03S |
$15.00 |
$60.4 |
$55.8 |
24.0 | 29.3 | 360 | SBCW |
BS, VSI |
Gliatech Inc. (GLIA) |
6/19 |
1.73S |
$12.00 | $20.7 |
$19.7 | 9.3 | 10.5 |
112 | CC | FS, VSI |
QLT PhotoTherapeutics Inc. (QLTIF) (2) |
7/24 |
1.0S |
$15.33 |
$15.3 | $14.7 |
27.2 |
ND | 417 |
NB |
SMcL |
Coulter Pharmaceutical Inc. (CLTR) |
7/31 |
2.65S |
$25.00 |
$66.1 |
$62.8 |
16.3 |
18.5 | 407 | BTAB |
HQ, PGE, PJI |
Anesta Corp. (NSTA) (3) |
12/17 |
2.8S | $21.25 |
$59.5 |
$55.6 |
12.4 |
14.1 |
264 | BRS | VBW |
1998 FOLLOW-ON TOTAL: $403.3M | ||||||||||
NOTES: | ||||||||||
* Number of shares (or units) sold in the offering includes those sold to satisfy overallotment options, in full or in part, where applicable. Likewise, gross proceeds include revenues for the sale of shares (or units) to satisfy overallotment options, in full or in part, where applicable. | ||||||||||
(1) NeuroSearch A/S' global follow-on offering consisted of a public offering and an institutional offering in Denmark and private placements outside Denmark. NeuroSearch's common shares are listed on the Copenhagen Stock Exchange. Prices have been converted at an exchange rate of DKr6.788/US$1. | ||||||||||
(2) QLT PhotoTherapeutics Inc.'s follow-on offering was conducted in Canada. Prices have been converted at an exchange rate of C$1.5/US$1. | ||||||||||
(3) Anesta Corp.'s follow-on stock offering consisted of a total of 3M shares. The company sold 2.8M shares and selling stockholders sold an additional 0.2M. |